Gallium 68 PSMA-11

Chemical NameGallium 68 PSMA-11
Dosage FormInjection (intravenous; 18.5 MBq/mL to 185 MBq/mL, 0.5 mCi/mL to 5 mCi/mL)
Drug ClassRadioactive diagnostic agents
SystemMale reproductive
CompanyUniversity of California
Approval Year2020

Indication

  • For positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy.
  • For positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
Last updated on 12/18/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Gallium 68 PSMA-11 Prescribing Information. 2020UCSF Radiopharmaceutical Facility, San Francisco, CA